Introduction
============

The excitatory amino acid glutamate serves as a fast excitatory neurotransmitter in the central nervous system ([@B01]), and excitotoxicity and oxidative toxicity are considered to be two major pathways responsible for glutamate-induced toxicity ([@B02],[@B03]). Excessive release of glutamate leading to excitotoxicity is responsible for neuronal injury associated with many acute and chronic brain diseases, such as brain ischemia, traumatic brain injury, and neurodegenerative disorders ([@B04],[@B05]).

Glycyrrhiza Radix, a crude Chinese traditional drug derived from *Glycyrrhiza uralensis*, *G. glabra* and *G. inflata*, exhibits various pharmacological activities including anti-inflammatory ([@B06]), anti-obesity ([@B07]), anti-virus ([@B08]), and anti-oxidative ([@B09]) effects. Glycyrrhizic acid (GA), a major component of Glycyrrhiza Radix, possesses anti-inflammatory and anti-viral effects ([@B10],[@B11]). Its structure is shown in [Figure 1A](#f01){ref-type="fig"}. A previous study demonstrated that GA exerts a neuroprotective effect against 6-hydroxydopamine-induced PC12 cell death via the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway ([@B12]). The protective effect of GA was also confirmed in rat primary neurons and hippocampal slices ([@B13]). However, the protective effects of GA against glutamate-induced differentiated PC12 (DPC12) cell damage and the underlying mechanisms have not been described.

![*A*, Chemical structure of glycyrrhizic acid (GA). *B*, GA enhanced cell viability in differentiated PC12 cells exposed to glutamate (Glu). Differentiated PC12 cells were pre-treated with GA for 3 h and then co-treated with or without Glu for another 24 h. Data are reported as a percentage (means±SD) of that from corresponding control cells (CTRL) (n=3). ^\#\#\#^P\<0.001 *vs* CTRL; \*P\<0.05 and \*\*\*P\<0.001 *vs* Glu-treated cells (one-way ANOVA followed by Dunn′s test).](1414-431X-bjmbr-47-09-00773-gf001){#f01}

Several signaling pathways are involved in the regulation of glutamate-induced neurotoxicity ([@B14],[@B15]). Alteration of mitochondrial function is one of the factors responsible for cell damage ([@B16]). Bax and B-cell lymphoma 2 (Bcl-2), located in mitochondria, are believed to be central regulators of mitochondrial function ([@B17]). Additionally, activation of both AKT and extracellular signal-regulated kinases (ERKs) is considered to contribute to cell proliferation and apoptosis ([@B18],[@B19]). Previous studies demonstrated that inhibition of phosphorylation of both AKT and ERKs is involved in glutamate-induced cell damage ([@B20],[@B21]).

Our study aimed to examine the effect of GA on attenuating glutamate cytotoxicity and its underlying mechanisms in DPC12 cells. Our results showed that GA improved cell viability and restored mitochondrial membrane potential dissipation. GA also normalized the expression of apoptosis-related proteins, including Bcl-2, Bax, cleaved caspase 3, and cytochrome C (Cyto C). Furthermore, GA pretreatment remarkably enhanced phosphorylation of ERKs but not AKT. Collectively, our findings demonstrated that ERKs and mitochondria-related pathways are essential for GA-mediated neuroprotection against glutamate-induced toxicity in DPC12 cells. This study provides evidence that supports the use of GA as a potential therapeutic agent for neurodegenerative diseases.

Material and Methods
====================

Cell culture
------------

PC12 cells (CRL-1721, passages \<10; obtained from ATCC) were grown in monolayers in collagen I-coated flasks with Dulbecco\'s modified Eagle\'s medium (Invitrogen, USA) supplemented with 10% horse serum (HS, Invitrogen), 5% fetal bovine serum (FBS, Invitrogen), penicillin (100 U/mL), and streptomycin (100 µg/mL, Invitrogen), under a humidified atmosphere containing 5% CO~2~ and 95% air at 37°C. The culture medium was changed every 3 days. PC12 cells were differentiated with 20 ng/mL nerve growth factor for 48 h, which was added to the culture medium containing 1% FBS and 1% HS. Cells were ready for treatment when they reached 80% confluence.

Cell viability analysis
-----------------------

Cell viability was measured by a quantitative colorimetric assay with 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich, USA) as reported previously ([@B22]). Briefly, PC12 cells were seeded onto 96-well plates at 1×10^4^ cells/well. After differentiation, cells were pretreated with 6.25-12.5 µM GA for 3 h and exposed to 20 mM glutamate for 24 h. In separate experiments, cells were pretreated with 10 µM LY294002 (PI3K inhibitor) or 10 µM PD98059 \[a mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor\] for 30 min, followed by treatment with 6.25-12.5 µM GA for 3 h and exposure to 20 mM glutamate for 24 h. Treated cells were incubated with MTT solution (0.5 mg/mL) for 4 h at 37°C in the dark. One hundred microliters of dimethyl sulfoxide were used to dissolve crystals. Absorbance was measured spectrophotometrically using a microplate reader (Bio-Rad, USA) at 540 nm. The viability of treated cells are reported as a percentage of that from corresponding control cells.

Mitochondrial membrane potential (MMP) analysis
-----------------------------------------------

5,5′,6,6′-Tetrachloro-1,1′,3,3′ tetraethylbenzimidazolylcarbocyanine iodide (JC-1, Sigma-Aldrich) staining was used to measure MMP changes. PC12 cells were seeded onto six-well plates at 1×10^5^ cells/well. After differentiation, cells were pretreated with 6.25 or 12.5 µM GA for 3 h and cotreated with glutamate for another 12 h. Next, cells were incubated with 2 µM JC-1 at 37°C for 10 min. After three washes with phosphate-buffered saline, fluorescent color in each group was examined using a fluorescence microscope (20×; Axio Observer Z1, CCD camera; Carl Zeiss, Germany). Red fluorescence indicated healthy cells with high MMP, whereas green fluorescence indicated apoptotic or unhealthy cells with low MMP. The average ratio of the red (590 nm) to green (540 nm) fluorescence intensity of each cell in the different groups was calculated using the ImageJ software (National Institutes of Health, USA). A total of 50 cells were calculated in each group. The values of treated cells are reported as a percentage of that from corresponding control cells.

Western blotting
----------------

Treated cells were lysed using radioimmunoprecipitation assay buffer (Sigma-Aldrich, USA) containing 1% protease inhibitor cocktail and 2% phenylmethanesulfonyl fluoride. Detection of Cyto C release from mitochondria to cytoplasm was performed using cytoplasmic extracts prepared as described previously ([@B23]). The supernatants were collected, and protein concentrations were determined by the Bradford method. Proteins were separated using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred electrophoretically onto nitrocellulose membranes (Bio Basic, USA). The transferred membranes were then blotted with antibodies as follows: phospho-ERKs (P-ERKs), total-ERKs (T-ERKs), phosphor-AKT (P-AKT), total-AKT (T-AKT), Bcl-2, Bax, cleaved caspase 3, Cyto C, and glyceraldehyde-3-phosphate dehydrogenase (all 1:1,000; Cell Signaling, USA) at 4°C overnight, followed by treatment with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, USA). The signals were detected with enhanced chemiluminescence detection kits (GE Healthcare, UK). The intensities of the bands were quantified with scanning densitometry using the Quantity One 4.5.0 software (Bio-Rad).

Statistical analysis
--------------------

One-way analysis of variance followed by *post hoc* multiple comparisons (Dunn\'s test) were performed to detect statistically significant differences (P\<0.05). Data are reported as means±SD.

Results
=======

Effect of GA against glutamate-induced cell damage in DPC12 cells
-----------------------------------------------------------------

GA alone did not affect DPC12 cell proliferation. Exposure to 20 mM glutamate for 24 h resulted in decreased viability of 77.3±0.6%; however, pretreatment with 6.25 and 12.5 μM GA significantly prevented the loss of cell viability, enhancing viability to 93.4±0.9% (P\<0.001) and 85.3±1.9% (P\<0.05), respectively ([Figure 1B](#f01){ref-type="fig"}).

GA restored glutamate-induced MMP dissipation
---------------------------------------------

JC-1 staining was used to examine MMP changes in treated cells. GA strongly restored glutamate-induced MMP dissipation, as demonstrated by an increment in red fluorescence emission compared with glutamate-treated cells ([Figure 2](#f02){ref-type="fig"}). As shown in the quantification data, compared to the control group, only 21.2±8.7% (P\<0.001) MMP was observed in glutamate-treated cells. Conversely, 6.25 and 12.5 μM GA pretreatment significantly restored MMP to 69.9±12.9% (P\<0.01) and 36.1±6.9% (P\<0.05), respectively ([Figure 2](#f02){ref-type="fig"}).

![Glycyrrhizic acid (GA) restored glutamate-disturbed mitochondrial function (20×; Scale bar: 100 µm). Differentiated PC12 cells were pretreated with 6.25 and 12.5 µM GA for 3 h and exposed to 20 mM glutamate (Glu) for 12 h. The changes of mitochondrial membrane potential (MMP) were determined by JC-1 staining. Red fluorescence indicates healthy cells with high MMP, whereas green fluorescence indicates apoptotic or unhealthy cells with low MMP. Average ratio of red (590 nm) to green (540 nm) fluorescent intensity of each cell in different groups was calculated (n=50) and data are reported as a percentage (means±SD) of that from corresponding control cells (CTRL). ^\#\#\#^P\<0.001 *vs* CTRL; \*P\<0.05 and \*\*P\<0.01 *vs* Glu-treated cells (one-way ANOVA followed by Dunn′s test).](1414-431X-bjmbr-47-09-00773-gf002){#f02}

Effects of GA on expression of Bcl-2, Bax, cleaved caspase 3, and Cyto C
------------------------------------------------------------------------

Compared to control cells, Bcl-2, Bax, cleaved caspase 3, and Cyto C (cytoplasm) expression levels were 75.9±4.3% (P\<0.05), 124.3±8.8% (P\<0.05), 155.5±10.6% (P\<0.01), and 119.8±3.2% (P\<0.05) in cells exposed to 20 mM glutamate for 24 h ([Figure 3](#f03){ref-type="fig"}). GA pretreatment (6.25 or 12.5 µM) strongly restored glutamate-reduced Bcl-2 levels to 102.3±12.7 or 95.1±10.9% (P\<0.05), normalized glutamate-increased Bax expression to 78.7±4.4 or 80.3±6.4% (P\<0.01), inhibited caspase 3 activity to 119.4±10.1% or 112.3±10.9% (P\<0.05), and suppressed Cyto C release to 102.2±7.9 or 98.9±6.8% (P\<0.05), respectively ([Figure 3](#f03){ref-type="fig"}).

![Glycyrrhizic acid (GA) restored the apoptotic alterations of apoptosis related proteins (Bcl-2, Bax, cleaved caspase 3 and cytoplasm Cyto C) caused by glutamate (Glu). Differentiated PC12 cells were pre-treated with GA for 3 h and then co-treated with Glu for another 24 h. Quantification data were normalized by GAPDH. Data are reported as a percentage (means±SD) of that from corresponding control cells (CTRL) (n=3). ^\#^P \<0.05, and ^\#\#^P \<0.01 *vs* CTRL; \*P\<0.05 and \*\*P\<0.01 *vs* Glu-treated cells (one-way ANOVA followed by Dunn′s test).](1414-431X-bjmbr-47-09-00773-gf003){#f03}

Activation of ERKs but not AKT contributes to GA-mediated neuroprotective effect
--------------------------------------------------------------------------------

Glutamate significantly suppressed P-ERK levels from 30 to 360 min (from 71.1±11.3 to 85.7±8.2%; P\<0.05) but did not affect T-ERK levels. Conversely, GA alone increased P-ERK expression at 180 and 360 min (132.2±7.2 and 132.3±12.2%, respectively; P\<0.05; [Figure 4A](#f04){ref-type="fig"}). GA pretreatment (6.25 µM) reversed the decrease in P-ERKs caused by glutamate, with a significant effect observed at 180 and 360 min (116.2±4.1 and 121.3±3.5%, respectively; P\<0.05; [Figure 4A](#f04){ref-type="fig"}). Further results showed that after pretreatment with 10 µM PD98059 for 30 min followed by a 3-h treatment of GA and exposure to glutamate for another 24 h, the neuroprotective effect of 6.25 µM GA on cell viability was significantly abrogated (80.7±4.5 *vs* 71.7±5.7%; P\<0.05; [Figure 4C](#f04){ref-type="fig"}). Collectively our results indicate that ERK activation was involved in GA-mediated neuroprotection in DPC12 cells.

![ERKs but not the AKT pathway were involved in the glycyrrhizic acid (GA)-mediated neuroprotective effect against glutamate-induced differentiated PC12 cell damage. *A*, *B*, Differentiated PC12 cells were treated with 6.25 µM GA or 20 mM glutamate (Glu) alone and collected at 0, 30, 60, 180, and 360 min. In co-treatment, following pretreatment with 6.25 µM GA for 3 h, cells were collected at 0, 30, 60, 180, and 360 min after Glu exposure. The expressions of P-ERKs, T-ERKs, P-AKT, T-AKT were detected by Western blot. Quantification data were normalized by related T-ERKs and T-AKT, respectively. *C*, *D*, Protective effects of GA against Glu on cell viability were abolished significantly by PD98059 but not by LY294002 pretreatment. Differentiated PC12 cells were pretreated with 10 µM PD98059 or LY294002 for 30 min, followed by treatment with 6.25 µM GA for 3 h and exposure to 20 mM Glu for 24 h. Cells were then collected for measurement of cell viability using the MTT method. ERKs: extracellular signal-regulated kinases; AKT: protein kinase B; P-ERKs: phospho-ERKs; T-ERKs: total-ERKs; P-AKT: phosphor-AKT; T-AKT: total-AKT. Data are reported as a percentage (mean±SD) of that from corresponding control cells (n=3). ^\#^P\<0.05, ^\#\#^P\<0.01, ^\#\#\#^P\<0.001 *vs* control cells; \*\*P\<0.01 *vs* Glu-treated cells; ^\$^P\<0.05 *vs* GA and Glu co-treated cells (one-way ANOVA followed by Dunn′s test).](1414-431X-bjmbr-47-09-00773-gf004){#f04}

Glutamate time-dependently reduced P-AKT levels from 30 to 360 min (12.1±2.2% to 19.6±8.9% reduced, respectively; P\<0.05). However, neither GA alone nor cotreatment with glutamate showed any effect on P-AKT levels ([Figure 4B](#f04){ref-type="fig"}). Furthermore, the effect GA on cell viability was not altered by a 30-min pretreatment with 10 µM LY290002 (a specific PI3K inhibitor) ([Figure 4D](#f04){ref-type="fig"}). These data indicate that the AKT pathway is not involved in this neuroprotective effect.

Discussion
==========

As a major compound of Glycyrrhiza Radix, GA has been studied for years. GA is neuroprotective in the post-ischemic brain mainly through anti-excitotoxic and anti-oxidative effects ([@B24]). GA protects against 3-morpholinosydnonimine-induced cell damage in lung epithelial cells ([@B25]). Recently, it was reported that GA inhibits extracellular high-mobility group box 1 cytokine activity and reduces the level of the inflammatory response, thus alleviating early brain injury and cerebrovasospasm ([@B26]). Our present study revealed that GA improved cell viability, restored mitochondrial dysfunction, and normalized expression of Bax, Bcl-2, cleaved caspase 3, and Cyto C compared with cells exposed to glutamate. GA enhanced P-ERK but not P-AKT levels. Further experiments employing MEK and PI3K inhibitors demonstrated that the ERK signaling pathway is essential in GA-mediated neuroprotection.

ERK and AKT activations are major factors related to cell survival ([@B14],[@B15]). Activated ERKs and stress-activated c-Jun N-terminal kinase-P38 have important roles in PC12 survival ([@B27]). Another study reported that sodium ferulate exerts neuroprotective effects against glutamate-induced apoptosis via ERK and AKT pathways ([@B21]). In the present study, both GA treatment alone and cotreatment with glutamate induced ERK phosphorylation, whereas glutamate downregulated P-ERK levels. However, neither GA treatment alone nor cotreatment with glutamate affected AKT activation. The presence of PD98059 but not LY294002 partially abrogated the protective effect on cell viability and further confirmed the role of ERKs in GA-mediated neuroprotection against glutamate-induced cytotoxicity in DPC12 cells.

On the other hand, growing experimental evidence indicates that mitochondrial function plays a central role in cell apoptosis ([@B28]). Results revealed that GA restored mitochondrial dysfunction, suppressed expression of Bax and cleaved caspase 3, enhanced expression of Bcl-2, and inhibited Cyto C release compared to glutamate-treated cells. Bcl-2 family members play crucial roles in regulating cell death, and the ratio Bcl-2/Bax is considered a hallmark for determining the relationship between cell death and mitochondrial dysfunction ([@B29]). It is believed that when MMP dissipation is observed, release of Cyto C from the mitochondria to the cytoplasm is enhanced. Caspases are a family of cysteine proteases that play pivotal roles in mediating neuronal apoptosis and neurodegeneration ([@B30]). As a critical apoptosis executioner, caspase 3 becomes activated in the cytosol and is translocated into the nucleus to cleave its nuclear substrates ([@B31]). Disruption of MMP unleashes the enzymatic apoptotic machinery of caspases, and of caspase 3 in particular, which executes apoptosis. Thus, it is not surprising that mitochondria-related pathways are involved in GA-mediated neuroprotection. Additionally, as reported, inhibition of ERK leads to downregulation of Bcl-2 and Bcl-xL expression ([@B32]). However, the relationship between ERK activation and mitochondrial function needs further study.

Although doses ranging from 1 to 50 µM GA were employed in the preliminary experiment, protective effects against glutamate-caused cell damage were only noted at 6.25 and 12.5 µM. The data suggested that 6.25 µM GA had a more potent effect. Interestingly, recent research reported that GA exerts an apoptotic effect in WEHI-3 mouse leukemia cells ([@B33]) and against DMH-induced colon carcinogenesis in Wistar rats ([@B34]). It appears that GA possesses biphasic properties, that is, GA shows protective activities in neurodegenerative diseases and neural injury, whereas it has apoptotic effects in cancer. The biphasic properties may also be related to the dosages employed. Detailed mechanisms underlying such biphasic effects deserve further study.

In conclusion, GA protects DPC12 cells against glutamate-induced neurotoxicity mainly through ERK and mitochondria-related pathways. Our findings provide experimental evidence that GA may be a candidate for treating or preventing neurodegenerative diseases.
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